Reactive oxygen species (ROS) have been implicated in the pathogenesis of Parkinson's disease. This suggests that antioxidant strategies may be useful in the treatment and/or prevention of this neurodegenerative disorder. We have developed and implemented two models for the central movement disorder and autonomic peripheral neuropathy, respectively, associated with Parkinson's disease. We propose to use these models to design and test antioxidant strategies we have previously developed for adjunctive use with ROS-generating chemotherapeutic agents. We will further use our studies of the biochemical effects of antioxidant treatment to develop a screening test for new antioxidant agents for use in Parkinson's disease and other ROS-related disorders. Specifically, we propose to test the hypothesis that recycling antioxidants increase expression of p21 wafl/cip1,enhance binding of HIF-1 and CREB to DNA, activate NF-kappaB, prevent ROS-induced morphological apoptosis, and decrease ROS-induced membrane phospholipid and protein nitration in culture models of Parkinson's disease. We will further test recycling antioxidants for their distribution to the CNS and peripheral compartments, and use this information to test CNS-penetrating and non-CNS-penetrating agents for efficacy in the central and autonomic nervous system models, respectively, of Parkinson's disease. Finally, we will test the hypothesis that the magnitude of induced in vitro biochemical change for each drug correlates with the degree of protection from the effects of ROS in the CNS or autonomic model. This latter study will pave the way for development of an in vitro screening test for new antioxidant strategies proposed for use in Parkinson's disease. This application specifically addresses the NINDS agenda for research in Parkinson's disease in its development of in vitro screening tests for putative therapeutic agents in general and antioxidants in particular for this disease, its development of animal models for the clinical aspects of Parkinson's disease, and its potential for further elucidation of the mechanisms of ROS-induced apoptosis in the nervous system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041297-02
Application #
6637909
Study Section
Special Emphasis Panel (ZRG1-BDCN-1 (01))
Program Officer
Oliver, Eugene J
Project Start
2002-07-01
Project End
2006-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
2
Fiscal Year
2003
Total Cost
$288,563
Indirect Cost
Name
Children's Hosp Pittsburgh/Upmc Health Sys
Department
Type
DUNS #
044304145
City
Pittsburgh
State
PA
Country
United States
Zip Code
15224
Schor, Nina F (2013) Why our patients (and we) need basic science research. Neurology 80:2070-5
Schor, Nina F (2013) Aiming at neuroblastoma and hitting other worthy targets. J Child Neurol 28:768-73
Tyurina, Yulia Y; Kapralov, Alexander A; Jiang, Jianfei et al. (2006) Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res 1093:71-82
Fritz, Melinda D; Mirnics, Zeljka K; Nylander, Karen D et al. (2006) p75NTR enhances PC12 cell tumor growth by a non-receptor mechanism involving downregulation of cyclin D2. Exp Cell Res 312:3287-97
Liang, Qinghua; Smith, Amanda D; Pan, Stephen et al. (2005) Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease. Biochem Pharmacol 70:1371-81
Tyurina, Yulia Y; Nylander, Karen D; Mirnics, Zeljka Korade et al. (2005) The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell 4:187-96
Weinberg, Ariella; Nylander, Karen D; Yan, Chaohua et al. (2004) Prevention of catecholaminergic oxidative toxicity by 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and its recycling complex with polynitroxylated albumin, TEMPOL/PNA. Brain Res 1012:13-21
Schor, N F; Kagan, V E; Liang, Ye et al. (2004) Exploiting oxidative stress and signaling in chemotherapy of resistant neoplasms. Biochemistry (Mosc) 69:38-44